GSK ends collaboration with IDEAYA for two candidates
GSK is ending its collaboration and licensing agreement with IDEAYA Biosciences for two clinical programs, Werner Helicase and Pol Theta, aimed at treating solid tumors. The agreement, established in 2020, involved synthetic lethality in oncology treatments and included profit sharing and royalties for IDEAYA, along with a $100M upfront payment.
Source: businessinsider The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments